Angela Balkwill

Angela Balkwill

Auto-generated profile, based on publicly available information

Angela Balkwill

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2015 in Circulation
Verified
Journal Article
Closed access
DCDexter Canoy
Dexter Canoy
VBValerie Beral
Valerie Beral
ABAngela Balkwill
Angela Balkwill
FWF. Lucy Wright
F. Lucy Wright
MKMary E. Kroll
Mary E. Kroll
BCBenjamin J. Cairns
Benjamin J. Cairns
Background—: Early menarche has been associated with increased risk of coronary heart disease (CHD), but most studies were relatively small and could not assess risk across a wide range of menarcheal ages; few have examined associations with other vascular diseases. We examined CHD, cerebrovascular disease, and hypertensive disease risks by age at menarche in a large prospective study of UK women. Methods and Results—: In 1.2 million women (mean±SD age, 56±5 years) without previous heart disease, stroke, or cancer, menarcheal age was reported to be 13 years by 25%, ≤10 years by 4%, and ≥17 years by 1%. After 11.6 years of follow-up, 73 378 women had first hospitalization for or death from CHD, 25 426 from cerebrovascular disease, and 249 426 from hypertensive disease. Using Cox regression, we calculated relative risks for each vascular outcome by single year of menarcheal age. The relationship was U-shaped for CHD. Compared with women with menarche at 13 years, the adjusted relative risk for CHD for menarche at ≤10 years of age was 1.27 (95% confidence interval, 1.22–1.31; P <0.0001) and for menarche at ≥17 years of age was 1.23 (95% confidence interval, 1.16–1.30; P <0.0001). U-shaped relationships were also seen for cerebrovascular and hypertensive disease, although the magnitudes of these risks for early and late menarche were smaller than those for CHD. Conclusions—: In this cohort, the relation of age at menarche to vascular disease risk was U shaped, with both early and late menarche being associated with increased risk. Associations were weaker for cerebrovascular and hypertensive disease than for CHD.

10 September 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SSS. Sweetland
S. Sweetland
VBV. Beral
V. Beral
ABA. Balkwill
A. Balkwill
BLB. Liu
B. Liu
VBV. S. Benson
V. S. Benson
OCon behalf of the Million Women Study Collaborators1
on behalf of the Million Women Study Collaborators1
Summary. Background: Current use of menopausal hormone therapy (HT) increases the risk of venous thromboembolism (VTE) and the formulations used may affect risk. Methods: A total of 1 058 259 postmenopausal UK women were followed by record linkage to routinely collected National Health Service hospital admission and death records. HT use and risk of VTE was examined using Cox regression to estimate relative risks (RRs) and 95% confidence intervals (CIs). Results: During 3.3 million years of follow‐up, 2200 women had an incident VTE, diagnosed, on average, 1.5 years after last reporting HT use. RRs in current vs. never users at last reporting varied by HT formulation: the risk was significantly greater for oral estrogen‐progestin than oral estrogen‐only therapy (RR = 2.07 [95%CI, 1.86–2.31] vs. 1.42 [1.21–1.66]), with no increased risk with transdermal estrogen‐only therapy (0.82 [0.64–1.06]). Among users of oral estrogen‐progestin, the risk from HT varied by progestin type, with significantly greater risks for preparations containing medroxyprogesterone acetate than other progestins (2.67 [2.25–3.17] vs. 1.91 [1.69–2.17]; Pheterogeneity = 0.0007). Current users of oral HT at last reporting had twice the risk of VTE in the first 2 years after starting HT than later (Pheterogeneity = 0.0006). Associations were similar for deep vein thrombosis with and without pulmonary embolism. Over 5 years, 1 in 660 who had never used HT were admitted to hospital for (or died from) pulmonary embolism, compared with 1 in 475 current users of oral estrogen‐only HT,1 in 390 users of estrogen‐progestin HT containing norethisterone/norgestrel, and 1 in 250 users of estrogen‐progestin HT containing medroxyprogesterone acetate. Conclusions: The risk of VTE varied considerably by HT formulation, being greatest in users of oral estrogen‐progestin HT, especially formulations containing medroxyprogesterone acetate.

11 March 2010 in BMJ
Verified
Journal Article
Open access
PDF file
BLBette Liu
Bette Liu
ABAngela Balkwill
Angela Balkwill
GRGillian Reeves
Gillian Reeves
VBValerie Beral
Valerie Beral
OCon behalf of the Million Women Study Collaborators.
on behalf of the Million Women Study Collaborators.
Objective To determine the relation between body mass index (BMI) and liver cirrhosis and the contribution that BMI and alcohol consumption make to the incidence of liver cirrhosis in middle aged women in the UK.Design Prospective cohort study (Million Women Study).Setting Women recruited from 1996 to 2001 in NHS breast screening centres and followed by record linkage to routinely collected information on hospital admissions and deaths.Participants 1 230 662 women (mean age 56 years at recruitment) followed for an average of 6.2 years.Main outcome measures Relative risk and absolute risk of first hospital admission with or death from liver cirrhosis adjusted for age, recruitment region, alcohol consumption, smoking, socioeconomic status, and physical activity.Results 1811 women had a first hospital admission with or died from liver cirrhosis during follow-up. Among women with a BMI of 22.5 or above, increasing BMI was associated with an increased incidence of liver cirrhosis: the adjusted relative risk of cirrhosis increased by 28% (relative risk 1.28, 95% confidence interval 1.19 to 1.38; P<0.001) for every 5 unit increase in BMI. Although the relative increase in the risk of liver cirrhosis per 5 unit increase in BMI did not differ significantly according to the amount of alcohol consumed, the absolute risk did. Among women who reported drinking less than 70 g alcohol per week, the absolute risk of liver cirrhosis per 1000 women over five years was 0.8 (0.7 to 0.9) for those with a BMI between 22.5 and 25 and 1.0 (0.9 to 1.2) for those with a BMI of 30 or more. Among women who reported drinking 150 g alcohol or more per week, the corresponding figures were 2.7 (2.1 to 3.4) and 5.0 (3.8 to 6.6).Conclusions Excess body weight increases the incidence of liver cirrhosis. In middle aged women in the UK, an estimated 17% of incident or fatal liver cirrhosis is attributable to excess body weight. This compares with an estimated 42% attributable to alcohol.

12 May 2004 in JAMA
Verified
Journal Article
Closed access
PDF file
EBEmily Banks
Emily Banks
VBValerie Beral
Valerie Beral
GRGillian Reeves
Gillian Reeves
ABAngela Balkwill
Angela Balkwill
IBIsobel Barnes
Isobel Barnes
Research from JAMA — Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women — ContextEvidence is limited on the effects of different patterns of use of postmenopausal hormone therapy on fracture incidence and particularly on the effects of ceasing use.ObjectiveTo investigate the effect of different patterns of hormone therapy use on fracture incidence.Design, Setting, and ParticipantsProspective study of 138 737 postmenopausal women aged 50 to 69 years recruited from the UK general population in 1996-1998 (the Million Women Study) and followed up for 1.9 to 3.9 years (average, 2.8 years) for fracture incidence.Main Outcome MeasureAdjusted relative risk (RR) for incident fracture (except fracture of the fingers, toes, and ribs) in hormone therapy users compared with never users at baseline.ResultsA total of 5197 women (3.7%) reported 1 or more fractures, 79% resulting from falls. Current users of hormone therapy at baseline had a significantly reduced incidence of fracture (RR, 0.62; 95% confidence interval [CI], 0.58-0.66; P<.001). This protection was evident soon after hormone therapy began, and the RR decreased with increasing duration of use (P = .001). Among current users at baseline the RR of fracture did not vary significantly according to whether estrogen-only, estrogen-progestin, or other types of hormones were used (RR [95% CI], 0.64 [0.58-0.71], 0.58 [0.53-0.64], and 0.67 [0.56-0.80], respectively; P = .19), nor did it vary significantly according to estrogen dose or estrogen or progestin constituents. The RR associated with current use of hormone therapy did not vary significantly according to 11 personal characteristics of study participants, including their age at menopause, body mass index, and physical activity. Past users of hormone therapy at baseline experienced no significant protection against fractures (RR, 1.07; 95% CI, 0.99-1.15); incidence rates returned to those of never-users within about a year of ceasing use.ConclusionsAll types of hormone therapy studied confer substantial protection against fracture while they are used. This protection appears rapidly after use commences and wears off rapidly after use ceases. The older women are, the greater is their absolute reduction in fracture incidence while using hormone therapy.

4 February 2007 in Rheumatology
Verified
Journal Article
Open access
PDF file
BLB Liu
B Liu
ABA Balkwill
A Balkwill
EBE Banks
E Banks
CCC Cooper
C Cooper
JGJ Green
J Green
VBV Beral
V Beral
Objectives . To examine the effect of height, weight and body mass index (BMI) on the risk of hip and knee replacement in middle-aged women. Methods . In a prospective cohort study 490 532 women aged 50–69 yrs who were recruited in the UK in 1996–2001 were followed over 2.9 yrs for incident primary hip and knee replacements. Results . Height, weight and BMI were all associated with the risk of hip and knee replacement. Comparing the tallest group (≥170 cm) with the shortest (<155 cm) the relative risks were 1.90 (95%CI 1.55–2.32) for hip replacement and 1.55 (95%CI 1.19–2.00) for knee replacement. Comparing the heaviest group (≥75 kg) with the lightest (<60 kg) the relative risks of hip and knee replacement were 2.37 (95%CI 2.04–2.75) and 9.71 (95%CI 7.39–12.77), respectively. Comparing obese women (BMI ≥ 30 kg/m 2 ) to women with a BMI < 22.5 kg/m 2 , the relative risks for hip and knee replacement were 2.47 (95%CI 2.11–2.89) and 10.51 (95%CI 7.85–14.08), respectively. These effects did not vary according to age, education, alcohol and tobacco consumption, or with use of hormonal therapies. Currently, an estimated 27% of hip replacements and 69% of knee replacements in middle-aged women in the UK are attributable to obesity. Conclusion . In middle-aged women, the risk of having a hip or knee replacement increases with both increasing height and increasing BMI. From a clinical perspective, relatively small increases in average BMI among middle-aged women are likely to have a substantial impact on the already increasing rates of joint replacement in the UK.

2 January 2014 in Gut
Verified
Journal Article
Open access
PDF file
FCFrancesca Crowe
Francesca Crowe
ABAngela Balkwill
Angela Balkwill
BCBenjamin J Cairns
Benjamin J Cairns
PAPaul N Appleby
Paul N Appleby
JGJane Green
Jane Green
VBValerie Beral
Valerie Beral
Background Previous prospective studies have found the incidence of intestinal diverticular disease decreased with increasing intakes of dietary fibre, but associations by the fibre source are less well characterised. We assessed these associations in a large UK prospective study of middle-aged women. Methods and findings During 6 (SD 1) years follow-up of 690 075 women without known diverticular disease who had not changed their diet in the last 5 years, 17 325 were admitted to hospital or died with diverticular disease. Dietary fibre intake was assessed using a validated 40-item food questionnaire and remeasured 1 year later in 4265 randomly-selected women. Mean total dietary fibre intake at baseline was 13.8 (SD 5.0) g/day, of which 42% came from cereals, 22% from fruits, 19% from vegetables (not potatoes) and 15% from potatoes. The relative risk (95% CI) for diverticular disease per 5 g/day fibre intake was 0.86 (0.84 to 0.88). There was significant heterogeneity by the four main sources of fibre (p<0.0001), with relative risks, adjusted for each of the other sources of dietary fibre of 0.84 (0.81 to 0.88) per 5 g/day for cereal, 0.81 (0.77 to 0.86) per 5 g/day for fruit, 1.03 (0.93 to 1.14) per 5 g/day for vegetable and 1.04 (1.02 to 1.07) per 1 g/day for potato fibre. Conclusions A higher intake of dietary fibre is associated with a reduced risk of diverticular disease. The associations with diverticular disease appear to vary by fibre source, and the reasons for this variation are unclear.